Anne Czichos/iStock Editorial via Getty Images Shares of SpringWorks Therapeutics ( NASDAQ: SWTX ) reached a session high on Thursday after The Wall Street Journal reported that Germany’s Merck KGaA ( OTCPK:MKGAF ) is closing in on a roughly $3.5B deal to acquire the cancer and rare disease drugmaker. According to.